Our Research

Molecular Theranostics specializes in developing and commercializing peptide based targeted molecular imaging agents and radionuclide therapeutics of high risk cancer at an early stage.

Pipelines

MT215
Targeted MRI contrast agent for prostate cancer.

MT218
Targeted radionuclide therapeutics for neuroendocrine tumors.

MT216
Targeted PET imaging agent for prostate and breast carcinomas.

Publications

Zheng Han, Yajuan Li, Sarah Roelle, Zhuxian Zhou, Yuchi Liu, Rob Sabatelle, Aidan DeSanto, Xin Yu, Hui Zhu, Cristina Magi-Galluzzi, and Zheng-Rong Lu. A Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI, Bioconjugate Chem. 2017, 28, 1031-1040.

Wu X, Yu G, Lindner D, Brady-Kalnay SM, Zhang Q, Lu ZR. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. Am J Nucl Med Mol Imaging. 2014, 4, 525-36.

Yajuan Li, Zheng Han, Sarah Roelle, Aidan DeSanto, Rob Sabatelle, Rebecca Schur, and Zheng-Rong Lu. Synthesis and Assessment of Peptide Gd–DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer, Molecular Pharmaceutics. 2017 14 (11), 3906-3915

Zheng Han, Zhuxian Zhou, Xiaoyue Shi, Junpeng Wang, Xiaohui Wu, Da Sun, Yinghua Chen, Hui Zhu, Cristina Magi-Galluzzi, and Zheng-Rong Lu. An EDB fibronectin specific peptide for prostate cancer targeting. Bioconjugate Chem. 2015, 26, 830-838.

Zhuxian Zhou, Mohammed Qutaish, Zheng Han, Rebecca M. Schur, Yiqiao Liu, David L. Wilson, Zheng-Rong Lu. MRI Detection of Breast Cancer Micrometastases with a fibronectin targeting contrast agent. Nature Commun. 2015, 6, 7984.

Han Z, Wu X, Roelle S, Chen C, Schiemann WP, Lu ZR. Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer. Nature communications. 2017 Sep 25.